DE69232516D1 - Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung - Google Patents

Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung

Info

Publication number
DE69232516D1
DE69232516D1 DE69232516T DE69232516T DE69232516D1 DE 69232516 D1 DE69232516 D1 DE 69232516D1 DE 69232516 T DE69232516 T DE 69232516T DE 69232516 T DE69232516 T DE 69232516T DE 69232516 D1 DE69232516 D1 DE 69232516D1
Authority
DE
Germany
Prior art keywords
interleukin
treatment
pct
inhibitory compound
neurological conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232516T
Other languages
English (en)
Other versions
DE69232516T2 (de
Inventor
Nancy Jane Rothwell
Gareth Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Manchester Manchester Gb, University of
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123161A external-priority patent/GB9123161D0/en
Priority claimed from GB919125670A external-priority patent/GB9125670D0/en
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of DE69232516D1 publication Critical patent/DE69232516D1/de
Application granted granted Critical
Publication of DE69232516T2 publication Critical patent/DE69232516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69232516T 1991-10-31 1992-11-02 Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung Expired - Lifetime DE69232516T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123161A GB9123161D0 (en) 1991-10-31 1991-10-31 Treatment of neurological conditions
GB919125670A GB9125670D0 (en) 1991-11-30 1991-11-30 Treatment of neurogical conditions
PCT/GB1992/002023 WO1993008820A1 (en) 1991-10-31 1992-11-02 Treatment of neurological conditions by an interleukin-1 inhibiting compound

Publications (2)

Publication Number Publication Date
DE69232516D1 true DE69232516D1 (de) 2002-05-02
DE69232516T2 DE69232516T2 (de) 2002-10-31

Family

ID=26299779

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232516T Expired - Lifetime DE69232516T2 (de) 1991-10-31 1992-11-02 Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung

Country Status (10)

Country Link
US (1) US6090775A (de)
EP (1) EP0610336B1 (de)
JP (1) JP3623501B2 (de)
AT (1) ATE214939T1 (de)
AU (3) AU2804192A (de)
CA (1) CA2122596C (de)
DE (1) DE69232516T2 (de)
DK (1) DK0610336T3 (de)
ES (1) ES2173871T3 (de)
WO (2) WO1993008819A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2003022213A2 (en) * 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
KR20080077237A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
CA2749537C (en) * 2009-01-09 2018-11-20 The Schepens Eye Research Institute, Inc. Il-1 antagonist compositions for corneal nerve regeneration and protection
EP4219538A3 (de) 2010-07-29 2023-08-09 Buzzard Pharmaceuticals AB Rezeptorbindende mittel
ES2884813T3 (es) 2013-03-13 2021-12-13 Buzzard Pharmaceuticals AB Formulaciones de citoquina quimérica para administración ocular

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100533A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
AU5921890A (en) * 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases

Also Published As

Publication number Publication date
EP0610336A1 (de) 1994-08-17
AU7648296A (en) 1997-02-13
WO1993008819A1 (en) 1993-05-13
US6090775A (en) 2000-07-18
EP0610336B1 (de) 2002-03-27
ATE214939T1 (de) 2002-04-15
CA2122596A1 (en) 1993-05-13
JP3623501B2 (ja) 2005-02-23
WO1993008820A1 (en) 1993-05-13
AU2804192A (en) 1993-06-07
ES2173871T3 (es) 2002-11-01
CA2122596C (en) 2008-06-03
AU2884592A (en) 1993-06-07
JPH07505608A (ja) 1995-06-22
DE69232516T2 (de) 2002-10-31
DK0610336T3 (da) 2002-07-22

Similar Documents

Publication Publication Date Title
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
DE69232516D1 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
ES2113652T3 (es) Pamoato de risperidona.
ATE136026T1 (de) Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
ATE185071T1 (de) Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms
PT651648E (pt) Composicoes farmaceuticas compreendendo il-6 e seu uso para o tratamento da doenca trombo-hemorragica destrutiva
DE59303446D1 (de) Neue bis-phenyl-hexene
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
EP0645963A4 (de)
NO921525D0 (no) L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
KR950016739A (ko) 강박관념 질환 및 소모성 질환을 억제하는 방법
ATE333287T1 (de) Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE UNIVERSITY OF MANCHESTER, MANCHESTER, GB

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE ZELLENTIN & PARTNER GBR, 81667 MUENCHEN

R071 Expiry of right

Ref document number: 610336

Country of ref document: EP